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Background: Contrast-induced nephropathy (CIN) has been recognized as a serious
complication of diagnostic coronary angiography and percutaneous coronary inter-
vention (PCI), and has been associated with prolonged hospitalization and adverse
clinical outcomes. A key step to minimize the risk for developing CIN is to identify
patients at risk for CIN.
Methods and results: We retrospectively investigated clinical factors associated
with the development of CIN in 60 stable angina patients who had undergone
elective PCI. The frequency of CIN was 13% (8/60). There were neither any signif-
icant differences in age, gender, baseline serum creatinine or hemoglobin levels,
nor in the rate of diabetes mellitus between the CIN and the non-CIN group.
However, the estimated glomerular ﬁltration rate (eGFR) was signiﬁcantly lower
(40.4± 11.4mL/min/1.73m2 vs. 57.4± 22.6mL/min/1.73m2, p = 0.044), and num-
ber of treated vessels (1.5± 0.8 vs. 1.2± 0.4, p = 0.039) and stents used (2.1± 0.6
vs. 1.4± 0.6, p = 0.007) were signiﬁcantly higher in the CIN group. In addition, the
amount of contrast medium was signiﬁcantly larger (272± 37mL vs. 201± 62mL,
p = 0.003) and the contrast medium volume (CMV) to eGFR ratio (CMV/eGFR) was
signiﬁcantly greater (7.4± 2.9 vs. 4.0± 2.0, p = 0.0001) in the CIN group. Stepwise
regression analysis showed that the CMV/eGFR ratio was a signiﬁcant independent
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predictor of CIN (p = 0.035). At a cut-off point of >5.1, the CMV/eGFR ratio exhibited
87.5% sensitivity and 74.5% speciﬁcity for detecting CIN.
Conclusion: The CMV/eGFR ratio could be a useful predictor of CIN developing after
elective PCI.














































































according to the operator’s preference. Iopamidol
370 (Nihon Schering, Osaka, Japan) warmed to 37 ◦C© 2009 Japanese Colleg
reserved.
ntroduction
ong-term mortality rates have been similar
etween patients with coronary artery disease
CAD) treated by percutaneous coronary interven-
ion (PCI) and by coronary artery bypass graft
CABG) [1]. However, contrast-induced nephropa-
hy (CIN) has been recognized as a serious
omplication of diagnostic coronary angiogra-
hy and PCI, and has been associated with
rolonged hospitalization and adverse clinical out-
omes [2—6]. A key step to minimize the risk for
eveloping CIN is to identify patients at risk for
IN.
Many risk factors associated with the develop-
ent of CIN have been reported [5—11]. Although
he most important risk factor is the pre-existing
enal dysfunction [5,6,9], the amount of contrast
edium has also been found to constitute a risk
or CIN [6]. The maximum radiographic contrast
ose (MRCD) is calculated using the following for-
ula: 5mL of contrast medium/kg body weight
maximum 300mL) divided by serum creatinine (Cr)
mg/dL) [12]. Freeman et al. reported that dos-
ng within the MRCD would reduce the risk of CIN
13]. Thus, both the volume of contrast medium
dministered and the presence of renal dysfunction
orrelate with the development of CIN. We hypoth-
sized that the contrast medium volume (CMV) to
stimated glomerular ﬁltration rate (eGFR) ratio
CMV/eGFR) would be a better predictor than
he dose of contrast medium or renal function
lone. Furthermore, patients with acute myocar-
ial infarction (AMI) subjected to emergency PCI
re at a higher risk of developing CIN than those
ndergoing elective interventions [14,15] because
everal factors may contribute to renal injury
nder those conditions; among them, hypoten-
ion or even shock, a large volume of contrast
edium, and the impossibility of renal prophylactic
herapy. In an attempt to minimize these condi-
ions, we retrospectively investigated the clinical
actors that could serve as predictors of CIN in sta-







e reviewed the clinical records of CIN in 60 stable
ngina patients who had been subjected to elec-
ive PCI. CIN was deﬁned as an increase in serum
r >0.5mg/dL or >25% [16,17] within 72 h after
CI. Patients with unstable angina, pre-existing
nd-stage renal disease requiring dialysis, and a his-
ory of exposure to contrast medium within one
eek before PCI were excluded from the anal-
sis. Patients were deﬁned with the metabolic
yndrome (MetS) according to the Japanese crite-
ia of the MetS [18]. According to these criteria,
atients were deﬁned with the MetS when visceral
besity plus two or more of the following three con-
itions were present: hypertension, dyslipidemia,
nd impaired fasting glucose. Visceral obesity was
eﬁned as waist circumference greater than 85 cm
n men or 90 cm in women. The diagnosis of hyper-
ension was based on a history of hypertension
r blood pressure above 130mmHg in systolic or
5mmHg in diastolic. Dyslipidemia was deﬁned as
riglyceride level greater than 150mg/dL and/or
igh-density lipoprotein cholesterol level less than
0mg/dL. Impaired fasting glucose was deﬁned as
asting plasma glucose (FPG) level greater than
10mg/dL or history of diabetes. Diabetes melli-
us (DM) was diagnosed as FPG level greater than
26mg/dL, hemoglobin A1c (HbA1c) level greater
han 6.5%, or treatment with either oral hypo-
lycemic agents or insulin.
CI procedures
CI procedures were performed using standard
echniques. Interventional devices were selectedas used as the radiographic contrast medium.
ntravenous hydration with 0.9% saline was pro-
ided at a rate of 1mL/kg/h for 12 h before and
fter PCI.
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Figure 1 Box-and-whisker plot showing contrast
medium volume (CMV) used for percutaneous coro-
nary intervention (PCI) in patients with and without
contrast-induced nephropathy (CIN). In these plots, lines
within boxes represent median values, the upper and
lower borders of boxes represent the 75th and 25th
percentiles, and the upper and lower bars outside the
boxes represent 90th and 10th percentiles, respectively.



















The eGFR was calculated using the modiﬁed
Modiﬁcation of Diet in Renal Disease (MDRD) equa-
tion [19]: eGFR (mL/min/1.73m2) = 194× serum
Cr (mg/dL)−1.094 ×Age (years)−0.287 (×0.739 for
female subjects). The CMV/eGFR ratio was calcu-
lated by dividing the volume of contrast medium
used for PCI by the patient’s eGFR.
Statistical analysis
Statistical analyses were performed using Statview
5.0 (SAS Institute, Cary, NC, USA). All values are
expressed as the mean± SD. Differences between
the means were compared by unpaired t-test
when the variables showed normal distribution,
or by the Mann—Whitney’s U test when they did
not. The signiﬁcance of any differences in pro-
portions was tested with Chi-square analysis. For
the stepwise regression analysis, nominal variables
(gender and hypertension) as well as numerical
variables (CMV/eGFR ratio, eGFR, baseline serum
Cr, CMV, age, FPG, HbA1c, and number of stents
used) were included. Analyses of the receiver-
operating characteristic (ROC) were conducted to
determine the cut-off value of the CMV/eGFR
ratio and baseline serum Cr level for predict-
ing CIN. Signiﬁcant difference was deﬁned as
p < 0.05.
Results
Baseline clinical characteristics are shown in
Table 1. Forty-eight of the 60 patients were
men and the mean age of the whole group
was 69± 8 years. Baseline serum Cr and
the eGFR values were 0.9± 0.3mg/dL and
55.1± 22.2mL/min/1.73m2, respectively. The
frequency of CIN was 13% (8/60). There were
neither any signiﬁcant differences in age, gen-
der, baseline serum Cr or hemoglobin levels,
nor in the rate of DM between the CIN and
the non-CIN group. However, the eGFR was sig-
niﬁcantly lower (40.4± 11.4mL/min/1.73m2
vs. 57.4± 22.6mL/min/1.73m2, p = 0.044) and
high-sensitivity C-reactive protein (hs-CRP)
level was signiﬁcantly higher (0.9± 1.2mg/L vs.
0.4± 0.4mg/L, p = 0.033) in the CIN group.Angiographic ﬁndings and lesion characteristics
in patients with and without CIN are shown in
Table 2. The number of diseased vessels tended to
be higher in the CIN group (p = 0.058). The number





d272± 37mL vs. 201± 62mL, p = 0.003).
nd stents used (2.1± 0.6 vs. 1.4± 0.6, p = 0.007)
n the CIN group were signiﬁcantly higher than in
he non-CIN group. There was no signiﬁcant dif-
erence in MRCD between the two groups. The
requency in excess of MRCD tended to be higher
n the CIN group, but not signiﬁcantly (13% vs. 4%,
= 0.296).
The amount of contrast medium was signiﬁ-
antly larger in the CIN group (272± 37mL vs.
01± 62mL, p = 0.003) (Fig. 1). In addition, the
MV/eGFR ratio was signiﬁcantly greater in the
IN group (7.4± 2.9 vs. 4.0± 2.0, p = 0.0001)
Fig. 2). Stepwise regression analysis showed that
he CMV/eGFR ratio was a signiﬁcant independent
redictor for the development of CIN (p = 0.035)
Table 3).
ROC analysis showed a higher area under the
urve for the CMV/eGFR ratio than for baseline
erum Cr level (0.839 vs. 0.282). At a cut-off
evel of >5.1, the CMV/eGFR ratio exhibited 87.5%
ensitivity, 74.5% speciﬁcity, 35.0% positive predic-
ive value, and 97.5% negative predictive value for
etecting CIN (Fig. 3).
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Table 1 Baseline clinical characteristics of patients with and without contrast-induced nephropathy (CIN).
Variables All patients, n = 60 CIN, n = 8 (13%) Non-CIN, n = 52 (87%) p-value
Age (years) 69± 8 70± 6 69± 9 0.848
Gender (male/female) 48/12 5/3 43/9 0.184
Height (cm) 160.8± 8.0 160.8± 9.0 160.8± 8.0 0.978
Body weight (kg) 63.5± 9.9 60.3± 14.4 64.0± 9.1 0.335
BMI (kg/m2) 24.5± 2.9 23.1± 3.6 24.7± 2.8 0.141
Cr (mg/dL) 0.9± 0.3 0.8± 0.2 0.9± 0.3 0.088
eGFR (mL/min/1.73m2) 55.1± 22.2 40.4± 11.4 57.4± 22.6 0.044
Hb (mg/dL) 13.8± 1.7 12.9± 1.9 13.9± 1.7 0.142
hs-CRP (mg/L) 0.5± 0.6 0.9± 1.2 0.4± 0.4 0.033
DM (%) 38 (63%) 3 (38%) 35 (67%) 0.103
FPG (mg/dL) 114± 34 98± 14 118± 36 0.14
HbA1c (%) 7.0± 1.3 6.3± 0.6 7.1± 1.4 0.326
Hypertension (%) 47 (78%) 5 (63%) 42 (81%) 0.243
Metabolic syndrome (%) 21 (35%) 3 (38%) 18 (35%) 0.874
Statins (%) 26 (43%) 6 (75%) 20 (38%) 0.052
Pitavastatin 14 3 11
Atorvastatin 7 2 5
Pravastatin 3 1 2
Others 2 0 2
ACE inhibitors or ARBs (%) 28 (47%) 2 (25%) 26 (50%) 0.187
-blockers (%) 19 (32%) 4 (50%) 15 (29%) 0.231
Data are expressed as the mean± SD or number (%).
BMI, body mass index; Cr, creatinine; eGFR, estimated glomerular ﬁltration rate; Hb, hemoglobin; hs-CRP, high-sensitivity C-
reactive protein; DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; ACE, angiotensin-converting
enzyme; ARB, angiotensin-receptor blocker.
Table 2 Angiographic ﬁndings and lesion characteristics in patients with and without contrast-induced nephropa-
thy (CIN).
Variables CIN, n = 8 (13%) Non-CIN, n = 52 (87%) p-value
Target vessel 0.86
LAD (%) 3 (38%) 21 (40%)
LCX (%) 1 (13%) 11 (21%)
RCA (%) 4 (50%) 19 (37%)
LMT (%) 0 (0%) 1 (2%)
Number of diseased vessels 0.058
1 vessel (%) 2 (25%) 21 (40%)
2 vessels (%) 6 (75%) 12 (23%)
3 vessels (%) 1.5± 0.8 19 (37%)
Number of treated vessels 1.5± 0.8 1.2± 0.4 0.039
CTO (%) 1 (13%) 1 (2%) 0.121
PCI device 0.806
Bare metal stent (%) 2 (25%) 11 (21%)
Drug-eluting stent (%) 6 (75%) 41 (79%)
Stent diameter (mm) 3.4± 0.4 3.1± 0.5 0.125
Stent length (mm) 22± 7 21± 5 0.61
Number of stents used 2.1± 0.6 1.4± 0.6 0.007
Max inﬂation pressure (atm) 18± 3 18± 3 0.901
MRCD (mL) 395± 115 336± 90 0.104
Excess of MRCD (%) 1 (13%) 2 (4%) 0.296
Data are expressed as the mean± SD or number (%).
LAD, left anterior descending coronary artery; LCX, left circumﬂex coronary artery; RCA, right coronary artery; LMT, left main trunk
coronary artery; CTO, chronic total occlusion; PCI, percutaneous coronary intervention; MRCD, maximum radiographic contrast
dose.
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CMV/eGFR ratio 0.068 0.0001 0.042 0.035
eGFR (mL/min/1.73m2) −0.004 0.044 Not entered
Cr (mg/dL) −0.283 0.088 Not entered
CMV (mL) 0.002 0.003 Not entered
Age (years) 0.001 0.848 Not entered
Gender 0.146 0.19 Not entered
Hypertension −0.124 0.25 Not entered
FPG (mg/dL) −0.002 0.14 Not entered
HbA1c (%) −0.037 0.326 Not entered
Number of stents used 0.176 0.007 Not entered
Stepwise regression analysis was performed using 10 variables to evaluate risk factors for the development of CIN.
Hypertension and female gender were assigned values of 1. Normotension and male gender were assigned values of 0.
CMV, contrast medium volume; eGFR, estimated glomerular ﬁltration rate; Cr, creatinine; FPG, fasting plasma glucose; HbA1c,
hemoglobin A1c.
Discussion
In this study, the CMV/eGFR ratio was a signiﬁ-
cant independent predictor of CIN developing after
elective PCI. The CMV/eGFR ratio represents both
Figure 2 Box-and-whisker plot showing the contrast
medium volume/estimated glomerular ﬁltration rate
(CMV/eGFR) ratio in patients with and without contrast-
induced nephropathy (CIN). In these plots, lines within
boxes represent median values, the upper and lower bor-
ders of boxes represent the 75th and 25th percentiles,
and the upper and lower bars outside the boxes represent
90th and 10th percentiles, respectively. The CMV/eGFR
ratio was signiﬁcantly higher in the CIN group (7.4± 2.9
vs. 4.0± 2.0, p = 0.0001).
the dose of contrast medium and the renal func-
tion. Therefore, our results demonstrate that the
volume of contrast medium administered and the
presence of renal dysfunction correlate with the
development of CIN.
The MRCD has been proposed as a predictor
of CIN because patients who received a large
amount of contrast medium over the MRCD showed
a higher frequency of CIN [12]. This formula
Figure 3 Receiver-operating characteristic analysis
shows a higher area under the curve for the con-
trast medium volume/estimated glomerular ﬁltration
rate (CMV/eGFR) ratio than for baseline serum creati-
nine (Cr) level (0.839 vs. 0.282). At a cut-off level of >5.1,
the CMV/eGFR ratio exhibited 87.5% sensitivity and 74.5%


















































































Rontrast medium volume to eGFR ratio for CIN
as applied retrospectively in 16,592 patients
ndergoing cardiac catheterization to evaluate its
sefulness as a predictor of CIN. Patients who
eceived contrast medium in excess of the MRCD
ere 6-fold more likely to develop CIN requir-
ng dialysis [13]. Thus, the amount of contrast
edium is an important risk factor for CIN [6].
he pathogenesis of CIN is not completely under-
tood. The renal medulla is uniquely susceptible
o ischemic injury, and contrast medium may
ause medullar hypoxia by shunting blood ﬂow
o the renal cortex [20,21]. It has been sug-
ested that the development of CIN is affected
y changes in renal hemodynamics because of
he effects of the contrast medium on the action
f many substances, including increased activity
f renal vasoconstrictors (vasopressin, angiotensin
I, dopamine-1, endothelin, and adenosine) and
ecreased activity of renal vasodilators (nitric
xide and prostaglandins) [22,23]. In animal mod-
ls of renal insufﬁciency, selective medullary injury
fter contrast administration has been shown,
ediated by vasoconstrictors such as endothelin,
asopressin, and adenosine [21,24]. Furthermore,
direct toxic effect of contrast medium on renal
pithelial cells has been shown [25] as well as
n increased red cell aggregation, possibly further
mpairing oxygen delivery [26].
In a previous report, contrast dose to Cr clear-
nce ratio has been reported to serve as a surrogate
ndex for the area under the curve [27]. The cut-
ff value of the contrast dose to Cr clearance ratio
ndicating a risk for CIN was 6.0 [28]. This cut-off
alue had a sensitivity of 79% and a speciﬁcity of 97%
or predicting CIN. In a recent study, the contrast
ose to Cr clearance ratio >3.7 was an indepen-
ent predictor for an early abnormal increase in
erum Cr after PCI [29]. According to previous stud-
es, the most important risk factor for developing
IN is pre-existing renal dysfunction [5,6,9]. How-
ver, the serum Cr level does not increase until
he GFR has decreased by 50% or more [30]. For
his reason, serum Cr level cannot show an early
tage of renal dysfunction. Furthermore, Cr clear-
nce value using Cockcroft—Gault formula usually
verestimates the GFR. Consequently, the GFR is
he most exact index of the patient’s renal func-
ion. Therefore, the CMV/eGFR ratio would more
losely represent both the dose of contrast medium
nd renal function than contrast dose to Cr clear-
nce ratio.
In this study, the levels of hs-CRP were signif-
cantly higher in the CIN group. We consider that
his was because the number of diseased vessels
ended to be higher in the CIN group. The num-
er of treated vessels and stents used in the CIN219
roup was signiﬁcantly higher than in the non-CIN
roup. Moreover, the amount of contrast medium
as signiﬁcantly larger in the CIN group. We think
hat in patients requiring complex PCI, the amount
f contrast medium used for angiography tends to
e higher and if those patients have early stage
enal dysfunction the contrast medium will further
orsen renal function leading to the development
f CIN. It may be preferable to perform PCI at
eparate stages for patients with multi-vessel dis-
ase, especially in those whose GFR is somewhat
ecreased.
tudy limitations
his study has several limitations. First, it was a
mall-scale and retrospective analysis conducted at
single institution. Second, the GFR was not mea-
ured directly. Third, there were some limitations
o obtain data on the patients’ real baseline condi-
ions before PCI because of dehydration or cardiac
llness. Future studies involving more patients from
variety of institutions need to be conducted in
rder to determine how effective this CMV/eGFR
atio really is.
onclusion
he CMV/eGFR ratio could be a useful predictor of
IN developing after elective PCI.
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